News Article

GSK is to acquire Boston-based clinical-stage oncology specialist Nuvalent for an equity value of approximately $10.6bn. This marks the British pharmaceutical giant’s largest transaction in over a decade.

GSK will pay 124 dollars per share in cash for all outstanding Nuvalent common stock – a 40 per cent premium to Nuvalent’s previous closing stock price. The tender offer is scheduled to expire on July 14, with the transaction expected to close in Q3.

The strategic acquisition centres on three precision medicine candidates targeting non-small cell lung cancer. The two lead assets, zidesamtinib and neladalkib, are both under priority FDA review and represent potential best-in-class small molecules engineered using structure-based drug design.

These assets carry FDA Breakthrough Therapy and Orphan Drug designations, complementing GSK’s late-stage pipeline including its phase three antibody-drug conjugate, risvutatug rezetecan.

For healthcare operators and investors, this transaction represents a major expansion of GSK’s oncology footprint. These near-launch assets are expected to generate high-margin commercial opportunities, helping to offset patent cliff pressures from the upcoming loss of exclusivity of GSK’s HIV drug dolutegravir between 2028 and 2030.